PAM50 intrinsic subtyping and pathologic responses to neoadjuvant trastuzumab-based chemotherapy in HER2-positive breast cancer.
P. Gomez Pardo
No relevant relationships to disclose
A. Prat
No relevant relationships to disclose
G. Bianchini
No relevant relationships to disclose
M. Pickl
Employment or Leadership Position - Roche
A. Belousov
Employment or Leadership Position - Roche
A. Koehler
Employment or Leadership Position - Roche
Stock Ownership - Roche
V. Semiglazov
No relevant relationships to disclose
W. Eiermann
No relevant relationships to disclose
S. Tjulandin
Honoraria - AstraZeneca; GlaxoSmithKline; Roche
M. Biakhov
No relevant relationships to disclose
A. Lluch
Honoraria - Roche
Other Remuneration - Roche
M. Zambetti
No relevant relationships to disclose
F. Vázquez-Mazón
No relevant relationships to disclose
L. Gianni
Consultant or Advisory Role - Genentech; GlaxoSmithKline; Novartis; Pfizer (U); Roche; Wyeth
J. Baselga
Consultant or Advisory Role - Roche